Abstract |
PCNU, a N-(2-chloroethyl)-N-nitrosourea, was administered to 37 previously treated patients with metastatic adenocarcinoma of the colon and rectum. The drug dose was 100 mg/m2, intravenously, over one hour for good risk patients and 75 mg/m2 for poor risk patients. Poor risk patients were defined as patients over 65 years of age or having liver enzymes greater than twice normal. The infusion was repeated at 6 week intervals. Seventeen patients (median performance status 80%) received PCNU at the 100 mg/m2 dose; 20 patients (median performance status 70%) received PCNU at the 75 mg/m2 dose. Complete responses were not observed. One patient treated with 100 mg/m2 achieved a partial response. Toxicity was primarily hematological with life-threatening leukopenia and thrombocytopenia observed in six patients. PCNU administered in the described dose schedule demonstrated little therapeutic efficacy in this patient population.
|
Authors | R Pazdur, M K Samson, L H Baker |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 6
Issue 2
Pg. 93-5
(Jun 1988)
ISSN: 0167-6997 [Print] United States |
PMID | 3170134
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Nitrosourea Compounds
- 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea
|
Topics |
- Adenocarcinoma
(drug therapy)
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Colonic Neoplasms
(drug therapy)
- Drug Evaluation
- Humans
- Middle Aged
- Nitrosourea Compounds
(adverse effects, therapeutic use)
- Rectal Neoplasms
(drug therapy)
|